Home › Research › TREM2 and immune genetics
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease
Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y et al.. Cell, 2017-08-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic variants of TREM2, a surface receptor required for microglial responses to neurodegeneration, including proliferation, survival, clustering, and phagocytosis. How TREM2 promotes such diverse responses is unknown. Here, we find that microglia in AD patients carrying TREM2 risk variants and TREM2-deficient mice with AD-like pathology have abundant autophagic vesicles, as do TREM2-deficient macrophages under growth-factor limitation or endoplasmic reticulum (ER) stress.
What this study adds
Evidence grade: Low
Lab analyses linked this to faulty mTOR signalling, which affects the cells' energy (ATP) and building-block supply. Activating a different receptor (Dectin-1) or adding cyclocreatine, a creatine-like compound, offset the problem only in cells grown in a dish, so this explains a possible mechanism and does not show any treatment works in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ulland, T. K., Song, W. M., Huang, S. C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., et al. (2017). TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. https://doi.org/10.1016/j.cell.2017.07.023
Vancouver
Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017. doi:10.1016/j.cell.2017.07.023. PMID: 28802038.
BibTeX
@article{ulland2017-28802038,
author = {Ulland, T. K. and Song, W. M. and Huang, S. C. and Ulrich, J. D. and Sergushichev, A. and Beatty, W. L. and Loboda, A. A. and Zhou, Y. and others},
title = {{TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease}},
journal = {Cell},
year = {2017},
doi = {10.1016/j.cell.2017.07.023},
pmid = {28802038},
url = {https://doi.org/10.1016/j.cell.2017.07.023}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- How TREM2 promotes such diverse responses is unknown.
- Here, we find that microglia in AD patients carrying TREM2 risk variants and TREM2-deficient mice with AD-like pathology have abundant autophagic vesicles, as do TREM2-deficient macrophages under growth-factor limitation or endoplasmic reticulum (ER) stress.
- Combined metabolomics and RNA sequencing (RNA-seq) linked this anomalous autophagy to defective mammalian target of rapamycin (mTOR) signaling, which affects ATP levels and biosynthetic pathways.
- Metabolic derailment and autophagy were offset in vitro through Dectin-1, a receptor that elicits TREM2-like intracellular signals, and cyclocreatine, a creatine analog that can supply ATP.
Why it matters
Weakened versions of the TREM2 gene raise Alzheimer's risk, and this study found that brain immune cells (microglia) from patients carrying these variants, and from TREM2-lacking mice with Alzheimer's-like changes, were packed with autophagic vesicles, a sign of the cell's self-digestion system running abnormally. Lab analyses linked this to faulty mTOR signalling, which affects the cells' energy (ATP) and building-block supply. Activating a different receptor (Dectin-1) or adding cyclocreatine, a creatine-like compound, offset the problem only in cells grown in a dish, so this explains a possible mechanism and does not show any treatment works in people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 59/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cell) |
| Journal's citation record | 4 / 4 | Cell: journal h-index 1,220 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,252 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 113.8 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 5 / 6 | Cited 34.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 5 / 6 | Cited by 144 other studies in this library |
| Still being cited | 4 / 4 | Cited 496 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Marco Colonna: h-index 172 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28802038) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
144 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.